WO2014143935A4 - Rapidly dispersible dosage form of oxcarbazepine - Google Patents
Rapidly dispersible dosage form of oxcarbazepine Download PDFInfo
- Publication number
- WO2014143935A4 WO2014143935A4 PCT/US2014/028125 US2014028125W WO2014143935A4 WO 2014143935 A4 WO2014143935 A4 WO 2014143935A4 US 2014028125 W US2014028125 W US 2014028125W WO 2014143935 A4 WO2014143935 A4 WO 2014143935A4
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- particle size
- drug
- matrix
- particles
- microns
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
- B29C—SHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
- B29C64/00—Additive manufacturing, i.e. manufacturing of three-dimensional [3D] objects by additive deposition, additive agglomeration or additive layering, e.g. by 3D printing, stereolithography or selective laser sintering
- B29C64/10—Processes of additive manufacturing
- B29C64/165—Processes of additive manufacturing using a combination of solid and fluid materials, e.g. a powder selectively bound by a liquid binder, catalyst, inhibitor or energy absorber
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B33—ADDITIVE MANUFACTURING TECHNOLOGY
- B33Y—ADDITIVE MANUFACTURING, i.e. MANUFACTURING OF THREE-DIMENSIONAL [3-D] OBJECTS BY ADDITIVE DEPOSITION, ADDITIVE AGGLOMERATION OR ADDITIVE LAYERING, e.g. BY 3-D PRINTING, STEREOLITHOGRAPHY OR SELECTIVE LASER SINTERING
- B33Y10/00—Processes of additive manufacturing
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B33—ADDITIVE MANUFACTURING TECHNOLOGY
- B33Y—ADDITIVE MANUFACTURING, i.e. MANUFACTURING OF THREE-DIMENSIONAL [3-D] OBJECTS BY ADDITIVE DEPOSITION, ADDITIVE AGGLOMERATION OR ADDITIVE LAYERING, e.g. BY 3-D PRINTING, STEREOLITHOGRAPHY OR SELECTIVE LASER SINTERING
- B33Y70/00—Materials specially adapted for additive manufacturing
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B33—ADDITIVE MANUFACTURING TECHNOLOGY
- B33Y—ADDITIVE MANUFACTURING, i.e. MANUFACTURING OF THREE-DIMENSIONAL [3-D] OBJECTS BY ADDITIVE DEPOSITION, ADDITIVE AGGLOMERATION OR ADDITIVE LAYERING, e.g. BY 3-D PRINTING, STEREOLITHOGRAPHY OR SELECTIVE LASER SINTERING
- B33Y80/00—Products made by additive manufacturing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7007—Drug-containing films, membranes or sheets
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
- B29K—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES B29B, B29C OR B29D, RELATING TO MOULDING MATERIALS OR TO MATERIALS FOR MOULDS, REINFORCEMENTS, FILLERS OR PREFORMED PARTS, e.g. INSERTS
- B29K2105/00—Condition, form or state of moulded material or of the material to be shaped
- B29K2105/0005—Condition, form or state of moulded material or of the material to be shaped containing compounding ingredients
- B29K2105/0035—Medical or pharmaceutical agents
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
- B29K—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES B29B, B29C OR B29D, RELATING TO MOULDING MATERIALS OR TO MATERIALS FOR MOULDS, REINFORCEMENTS, FILLERS OR PREFORMED PARTS, e.g. INSERTS
- B29K2105/00—Condition, form or state of moulded material or of the material to be shaped
- B29K2105/0058—Liquid or visquous
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
- B29K—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES B29B, B29C OR B29D, RELATING TO MOULDING MATERIALS OR TO MATERIALS FOR MOULDS, REINFORCEMENTS, FILLERS OR PREFORMED PARTS, e.g. INSERTS
- B29K2105/00—Condition, form or state of moulded material or of the material to be shaped
- B29K2105/25—Solid
- B29K2105/251—Particles, powder or granules
Abstract
Claims
STATEMENT UNDER ARTICLE 19 (1 )
Claims now require non-compressed matrix comprising two different grades of OXC differing in particle size and further specify ranges for effective particle size and native drug particle size as well as for ratio thereof.
Examiner argues Sehgal discloses a rapidly dispersible dosage form containing oxcarbazepine and dissolving in <2 minutes. Examiner acknowledges Sehgal fails to suggest a 3DP dosage form exhibiting a dispersion time of 15 sec or less and relies upon Yoo as disclosing rapidly dispersible dosage forms exhibiting a dispersion time of 15 sec or less. Examiner relies upon Blau as disclosing formulations containing 35-60% of oxcarbazepine.
Neither Sehgal, Yoo nor Blau discloses use of two different grades of drug particles having different native particle sizes, None of the references discloses need to balance effective particle size and native drug particle size during 3DP.
Sehgal and Blau illustrate wide range of results when different drug particle sizes and granulation approaches are used with tabletting. All achieve much slow disintegration times.
Sehgal (Dl) only discloses a compressed dosage form and focuses on use of wetting agent to overcome the need for small particle size oxcarbazepine. ([0003], [0011], [0020]). Sehgal strongly suggests use of larger particles of oxcarbazepine (median particle size: 20-50 microns) in order to obtain "best results". Examples 1-4 ([0040]-[0048]) employ oxcarbazepine with median particle size of about 26 microns. Sehgal only suggests granulated particles and only achieves a "disintegration time in water <2 minutes."
Yoo's (D2) 3DP non-compressed matrices have a dispersion time of 15 sec or less; however, Yoo does not recognize the importance of balancing particle size of native drug versus that of drug-containing particles, Yoo does not contemplate granulation of small drug particles into larger drug-containing particles in order overcome problems caused by small drug particles during 3DP process. Yoo only achieves <15 sec disintegration time using ungranulated drug particles.
Blau (D3) discloses formulations containing granulated OXC having at least two different particle size populations. The granulated particles are used in compressed tablets and have a disintegration time of <30 mill- ([0025]) Proper combination of Sehgal, Yoo and Blau suggests that granulation of drug causes a slower rather than faster dMotegration time. There is no suggestion or enablement a priori that one can achieve dispersion in <15 sec in a 3DP matrix containing granulated particles comprising OXC particles of two different sizes. There is no certainty that a satisfactory dosage form, e.g. with suitable hardness and/or surface features, could even be produced by 3DP.
The instant specification discloses the "effective particle size" of OXC in the bulk powder must be increased without increasing the "actual particle size" of the drug ([0013]) for the purpose of facilitating three-dimensional printing of acceptable dosage forms while keeping the actual drug particle size small to facilitate drug absorption. ([0023], [0024], [004]).
Claimed invention provides preferred ranges for effective particle size and native drug particle size and for ratio thereof and requires combination of two different grades of OXC differing in particle size.
Respectfully submitted,
Priority Applications (14)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
MX2015012136A MX364381B (en) | 2013-03-15 | 2014-03-14 | Rapidly dispersible dosage form of oxcarbazepine. |
ES14763545T ES2761265T3 (en) | 2013-03-15 | 2014-03-14 | Rapidly dispersible oxcarbazepine dosage form |
EP14763545.2A EP2968354B1 (en) | 2013-03-15 | 2014-03-14 | Rapidly dispersible dosage form of oxcarbazepine |
CN201480014727.3A CN105050604B (en) | 2013-03-15 | 2014-03-14 | Fast dispersing dosage forms of oxcarbazepine |
JP2016502709A JP6463333B2 (en) | 2013-03-15 | 2014-03-14 | Rapidly dispersible dosage form of oxcarbazepine |
AU2014228063A AU2014228063B2 (en) | 2013-03-15 | 2014-03-14 | Rapidly dispersible dosage form of oxcarbazepine |
CA2906107A CA2906107C (en) | 2013-03-15 | 2014-03-14 | Rapidly dispersible dosage form of oxcarbazepine |
US14/837,493 US9314429B2 (en) | 2013-03-15 | 2015-08-27 | Rapidly dispersible dosage form of oxcarbazepine |
HK16101293.4A HK1213472A1 (en) | 2013-03-15 | 2016-02-04 | Rapidly dispersible dosage form of oxcarbazepine |
US15/045,711 US9616018B2 (en) | 2013-03-15 | 2016-02-17 | Rapidly dispersible dosage form of oxcarbazepine |
HK16102379.9A HK1214173A1 (en) | 2013-03-15 | 2016-03-02 | Rapidly dispersible dosage form of oxcarbazepine |
US15/437,966 US10028909B2 (en) | 2013-03-15 | 2017-02-21 | Rapidly dispersible dosage form of oxcarbazepine |
AU2017203365A AU2017203365B2 (en) | 2013-03-15 | 2017-05-19 | Rapidly dispersible dosage form of oxcarbazepine |
US16/015,552 US20180296479A1 (en) | 2013-03-15 | 2018-06-22 | Rapidly Dispersible Dosage Form with High Drug Content |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361791726P | 2013-03-15 | 2013-03-15 | |
US61/791,726 | 2013-03-15 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/837,493 Continuation US9314429B2 (en) | 2013-03-15 | 2015-08-27 | Rapidly dispersible dosage form of oxcarbazepine |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2014143935A1 WO2014143935A1 (en) | 2014-09-18 |
WO2014143935A4 true WO2014143935A4 (en) | 2014-11-20 |
Family
ID=51537567
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2014/028125 WO2014143935A1 (en) | 2013-03-15 | 2014-03-14 | Rapidly dispersible dosage form of oxcarbazepine |
Country Status (10)
Country | Link |
---|---|
US (4) | US9314429B2 (en) |
EP (1) | EP2968354B1 (en) |
JP (2) | JP6463333B2 (en) |
CN (1) | CN105050604B (en) |
AU (2) | AU2014228063B2 (en) |
CA (1) | CA2906107C (en) |
ES (1) | ES2761265T3 (en) |
HK (2) | HK1213472A1 (en) |
MX (1) | MX364381B (en) |
WO (1) | WO2014143935A1 (en) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9339489B2 (en) | 2013-03-15 | 2016-05-17 | Aprecia Pharmaceuticals Company | Rapid disperse dosage form containing levetiracetam |
WO2015168463A1 (en) * | 2014-05-02 | 2015-11-05 | University Of Louisville Research Foundation, Inc. | Methods for fabricating dental restorations |
WO2016192680A1 (en) | 2015-06-03 | 2016-12-08 | Triastek, Inc. | Dosage forms and use thereof |
CN105770899A (en) * | 2016-03-07 | 2016-07-20 | 北京诺康达医药科技有限公司 | Quick release agent of large-dose medicine and preparation method of quick release agent |
AU2017235598A1 (en) * | 2016-03-18 | 2018-08-09 | Grünenthal GmbH | Floating pharmaceutical dosage form |
US10765658B2 (en) | 2016-06-22 | 2020-09-08 | Mastix LLC | Oral compositions delivering therapeutically effective amounts of cannabinoids |
GB201612853D0 (en) | 2016-07-25 | 2016-09-07 | Univ Central Lancashire | Solid dosage form production |
US10703549B2 (en) | 2017-06-30 | 2020-07-07 | The Procter And Gamble Company | Water soluble containers and methods of making them |
CN111225983A (en) * | 2017-10-26 | 2020-06-02 | 默克专利股份公司 | Method for performing cell culture |
WO2019137200A1 (en) | 2018-01-09 | 2019-07-18 | Triastek, Inc. | Oral drug dosage forms comprising a fixed-dose of an adhd non-stimulant and an adhd stimulant |
CN116115554A (en) | 2018-10-15 | 2023-05-16 | 阿普雷奇亚制药有限责任公司 | Method and system for forming dosage forms in packages |
EP3662898A1 (en) * | 2018-12-07 | 2020-06-10 | Tillotts Pharma AG | Solid composition comprising mesalazine |
CN113302410A (en) | 2019-01-18 | 2021-08-24 | 株式会社Ihi | Thrust foil bearing |
EP3789015A1 (en) * | 2019-09-05 | 2021-03-10 | Universität Innsbruck | Fast consolidating compounds |
ES2828509B2 (en) | 2019-11-26 | 2022-03-09 | Fund Idonial | COMPOSITION FOR 3D PRINTING OF SEMI-SOLID DRUGS |
CN116018131A (en) * | 2020-06-26 | 2023-04-25 | 阿普雷奇亚制药有限责任公司 | Fast orodispersible tablet with inner cavity |
WO2024038000A1 (en) * | 2022-08-18 | 2024-02-22 | Merck Patent Gmbh | Process for the manufacture of a solid pharmaceutical administration form |
Family Cites Families (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1548022A (en) | 1976-10-06 | 1979-07-04 | Wyeth John & Brother Ltd | Pharmaceutial dosage forms |
US4642903A (en) | 1985-03-26 | 1987-02-17 | R. P. Scherer Corporation | Freeze-dried foam dosage form |
US4855326A (en) | 1987-04-20 | 1989-08-08 | Fuisz Pharmaceutical Ltd. | Rapidly dissoluble medicinal dosage unit and method of manufacture |
EP0418596A3 (en) | 1989-09-21 | 1991-10-23 | American Cyanamid Company | Controlled release pharmaceutical compositions from spherical granules in tabletted oral dosage unit form |
US5178878A (en) | 1989-10-02 | 1993-01-12 | Cima Labs, Inc. | Effervescent dosage form with microparticles |
US5578322A (en) | 1990-11-30 | 1996-11-26 | Yamanouchi Pharmaceutical Co., Ltd. | Quick release coated preparation |
DE4200821A1 (en) | 1992-01-15 | 1993-07-22 | Bayer Ag | TASTE-MASKED PHARMACEUTICAL AGENTS |
US5518730A (en) | 1992-06-03 | 1996-05-21 | Fuisz Technologies Ltd. | Biodegradable controlled release flash flow melt-spun delivery system |
US5380473A (en) | 1992-10-23 | 1995-01-10 | Fuisz Technologies Ltd. | Process for making shearform matrix |
ATE208615T1 (en) | 1993-07-09 | 2001-11-15 | Scherer Corp R P | METHOD FOR PRODUCING FREEZE-DRIED MEDICINAL DOSAGE FORMS |
US5490962A (en) * | 1993-10-18 | 1996-02-13 | Massachusetts Institute Of Technology | Preparation of medical devices by solid free-form fabrication methods |
CA2134611C (en) | 1994-10-28 | 2002-12-24 | Richard John Yarwood | Process for preparing solid pharmaceutical dosage forms |
US5607697A (en) | 1995-06-07 | 1997-03-04 | Cima Labs, Incorporated | Taste masking microparticles for oral dosage forms |
US6471992B1 (en) | 1997-02-20 | 2002-10-29 | Therics, Inc. | Dosage form exhibiting rapid disperse properties, methods of use and process for the manufacture of same |
FR2766089B1 (en) | 1997-07-21 | 2000-06-02 | Prographarm Lab | IMPROVED MULTIPARTICULAR TABLET WITH RAPID DELIVERY |
TR200200710T2 (en) | 1999-07-09 | 2002-08-21 | Ortho-Mcneil Pharmaceutical, Inc. | Pharmaceutical liquid compositions produced to prevent the unpleasant taste of the drug. |
DE19940944B4 (en) | 1999-08-31 | 2006-10-12 | Grünenthal GmbH | Retarded, oral, pharmaceutical dosage forms |
JP5178982B2 (en) * | 2000-05-18 | 2013-04-10 | セリックス, インコーポレイテッド | Encapsulation of the toxic core in a non-toxic region in an oral dosage form |
MXPA03008057A (en) | 2001-03-05 | 2004-10-15 | Johnson & Johnson | Taste masked pharmaceutical compositions. |
MXPA03010549A (en) * | 2001-05-18 | 2004-05-27 | Ranbaxy Lab Ltd | Oxcarbazepine dosage forms. |
CA2463481A1 (en) * | 2001-10-29 | 2003-05-22 | Therics, Inc. | Three-dimensional suspension printing of dosage forms |
CA2497176A1 (en) | 2002-09-04 | 2004-03-18 | Ranbaxy Laboratories Limited | Taste masked dosage forms and processes for their preparation |
WO2004052345A1 (en) | 2002-12-11 | 2004-06-24 | Ranbaxy Laboratories Limited | Coating composition for taste masking coating and methods for their application and use |
JP4739217B2 (en) | 2003-05-07 | 2011-08-03 | サムヤン コーポレイション | Highly plastic granules for making fast dissolving tablets |
FR2858556B1 (en) | 2003-08-06 | 2006-03-10 | Galenix Innovations | DISPERSIBLE AND / OR ORODISPERSIBLE SOLID PHARMACEUTICAL COMPOSITION, NOT PELLETIZED, CONTAINING AT LEAST THE METFORMIN ACTIVE INGREDIENT, AND PROCESS FOR PREPARING THE SAME |
US20070154550A1 (en) | 2003-08-28 | 2007-07-05 | Potdar Arti | Pharmaceutical composition comprising anticonvulsant with taste mask coating |
US20060127479A1 (en) | 2004-10-08 | 2006-06-15 | Natrajan Kumaraperumal | Solvent free taste masked pharmaceutical compositions |
WO2006070406A1 (en) * | 2004-12-29 | 2006-07-06 | J.B. Chemicals & Pharmaceuticals Ltd | Bilayer tablets of oxcarbazepine for controlled delivery and a process of preparation thereof |
US20060182796A1 (en) | 2005-02-03 | 2006-08-17 | Abrika Pharmaceuticals, Inc. | Taste masked pharmaceutical compositions |
US20070092553A1 (en) | 2005-10-21 | 2007-04-26 | Pfab Lp | Compositions and methods of making rapidly dissolving lonically masked formulations |
EP2029118A2 (en) * | 2006-01-31 | 2009-03-04 | Teva Pharmaceutical Industries, Inc. | Oxcarbazepine pharmaceutical formulation and its method of preparation, wherein oxcarbazepine has a broad and multi-modal particle size distribution |
US20070178164A1 (en) * | 2006-01-31 | 2007-08-02 | Sigal Blau | Pharmaceutical formulations of oxcarbazepine and methods for its preparation |
US20070248684A1 (en) * | 2006-01-31 | 2007-10-25 | Sigal Blau | Pharmaceutical formulations of oxcarbazepine and methods for its preparation |
EP2010499A4 (en) * | 2006-04-21 | 2012-07-18 | Alphapharm Pty Ltd | Pharmaceutical compositions of oxcarbazepine with a median particle size of 15 to 30 microns |
WO2008141751A2 (en) * | 2007-05-23 | 2008-11-27 | Ratiopharm Gmbh | Pharmaceutical compositions comprising oxcarbazepine |
WO2010092828A1 (en) | 2009-02-12 | 2010-08-19 | 富士化学工業株式会社 | Disintegrating particle composition and rapidly disintegrating compression-molded material comprising same |
US20100285130A1 (en) | 2009-05-06 | 2010-11-11 | Monosol Rx, Llc | Coating of complexed actives in film formulations |
EP2437734A2 (en) | 2009-06-04 | 2012-04-11 | Basf Se | Orally disintegrating dosage forms containing taste-masked active ingredients |
JP2013502388A (en) | 2009-08-19 | 2013-01-24 | バイエル ファーマ アクチエンゲゼルシャフト | Drug delivery system (wafer) for pediatric use |
US20110212171A1 (en) | 2010-01-08 | 2011-09-01 | Eurand, Inc. | Taste masked topiramate composition and an orally disintegrating tablet comprising the same |
US9381154B2 (en) * | 2011-06-09 | 2016-07-05 | Xerox Corporation | Direct inkjet fabrication of drug delivery devices |
-
2014
- 2014-03-14 JP JP2016502709A patent/JP6463333B2/en active Active
- 2014-03-14 CN CN201480014727.3A patent/CN105050604B/en active Active
- 2014-03-14 EP EP14763545.2A patent/EP2968354B1/en active Active
- 2014-03-14 WO PCT/US2014/028125 patent/WO2014143935A1/en active Application Filing
- 2014-03-14 CA CA2906107A patent/CA2906107C/en active Active
- 2014-03-14 ES ES14763545T patent/ES2761265T3/en active Active
- 2014-03-14 MX MX2015012136A patent/MX364381B/en active IP Right Grant
- 2014-03-14 AU AU2014228063A patent/AU2014228063B2/en active Active
-
2015
- 2015-08-27 US US14/837,493 patent/US9314429B2/en active Active
-
2016
- 2016-02-04 HK HK16101293.4A patent/HK1213472A1/en unknown
- 2016-02-17 US US15/045,711 patent/US9616018B2/en active Active
- 2016-03-02 HK HK16102379.9A patent/HK1214173A1/en unknown
-
2017
- 2017-02-21 US US15/437,966 patent/US10028909B2/en active Active
- 2017-05-19 AU AU2017203365A patent/AU2017203365B2/en active Active
-
2018
- 2018-06-22 US US16/015,552 patent/US20180296479A1/en not_active Abandoned
- 2018-09-14 JP JP2018172088A patent/JP2019006812A/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
MX2015012136A (en) | 2015-11-25 |
US9616018B2 (en) | 2017-04-11 |
JP2019006812A (en) | 2019-01-17 |
WO2014143935A1 (en) | 2014-09-18 |
JP2016513724A (en) | 2016-05-16 |
US10028909B2 (en) | 2018-07-24 |
MX364381B (en) | 2019-04-25 |
US20180296479A1 (en) | 2018-10-18 |
AU2017203365A1 (en) | 2017-06-08 |
AU2014228063A1 (en) | 2015-10-08 |
US9314429B2 (en) | 2016-04-19 |
JP6463333B2 (en) | 2019-01-30 |
EP2968354B1 (en) | 2019-11-13 |
ES2761265T3 (en) | 2020-05-19 |
HK1214173A1 (en) | 2016-07-22 |
EP2968354A4 (en) | 2016-01-20 |
CN105050604A (en) | 2015-11-11 |
CN105050604B (en) | 2021-10-26 |
AU2017203365B2 (en) | 2019-07-25 |
AU2014228063B2 (en) | 2017-04-20 |
US20150366802A1 (en) | 2015-12-24 |
US20170172919A1 (en) | 2017-06-22 |
CA2906107A1 (en) | 2014-09-18 |
EP2968354A1 (en) | 2016-01-20 |
US20160250145A1 (en) | 2016-09-01 |
CA2906107C (en) | 2021-08-24 |
HK1213472A1 (en) | 2016-07-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2014143935A4 (en) | Rapidly dispersible dosage form of oxcarbazepine | |
JP2016513724A5 (en) | ||
EP2854759B1 (en) | Dosage forms comprising apixaban and matrix former | |
CN103655539B (en) | A kind of oral solid formulation of canagliflozin and preparation method thereof | |
AU2012250862B2 (en) | Rapid dissolve tablet compositions for vaginal administration | |
CA2611520A1 (en) | Method and composition for pharmaceutical product | |
EP2285357A1 (en) | Pharmaceutical compositions comprising brivaracetam | |
CN106860414B (en) | anti-HIV compound preparation and preparation method and application thereof | |
JPWO2011074660A1 (en) | Elution stability formulation | |
JP2020114834A (en) | Ceritinib formulation | |
ZA200504425B (en) | Pharmaceutical formulations comprins beta-2 andrenoreceptor antagonists and xanthines | |
WO2019012552A1 (en) | Compositions of ferric organic compounds | |
KR101583452B1 (en) | A pharmaceutical composition for treating gastrointestinal diseases | |
KR101697773B1 (en) | Modified release composition comprising doxofylline | |
RU2367438C2 (en) | Controlled release trimetazidine matrix tablet | |
KR101471240B1 (en) | Burst drug release compositions | |
Shetty et al. | Design and evaluation of sustained release matrix tablets of etodolac | |
CN104606162A (en) | Pramipexole dihydrochloride sustained release preparation and preparation method thereof | |
Ramesh et al. | Design and evaluation of sustained release matrix tablets of Levofloxacin employing almond gum | |
JP2013121951A (en) | Stable solid preparation and method for producing the same | |
WO2018130943A1 (en) | Oral pharmaceutical composition of lurasidone and preparation thereof | |
CN104337783B (en) | A kind of capecitabine tablet and preparation method thereof | |
Nishanth et al. | Formulation Development and Evaluation of Bilayer Tablets of Telmisartan for Immediate Release and Metformin Hydrochloride for Sustained Release. | |
Singh et al. | Design development and evaluation of matrix tablets of Ambroxol Hydrochloride: In Vitro–In Vivo Study | |
Gupta et al. | FORMULATION AND EVALUATION OF GASTRO-RETENTIVE TABLETS OF DIMENHYDRINATE |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 201480014727.3 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 14763545 Country of ref document: EP Kind code of ref document: A1 |
|
DPE1 | Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2015/012136 Country of ref document: MX |
|
ENP | Entry into the national phase |
Ref document number: 2906107 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2016502709 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2014228063 Country of ref document: AU Date of ref document: 20140314 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2014763545 Country of ref document: EP |